The Economic Burden of Biological Drugs in Rheumatoid Arthritis Treatment
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14160%2F24%3A00135350" target="_blank" >RIV/00216224:14160/24:00135350 - isvavai.cz</a>
Result on the web
<a href="https://www.valuehealthregionalissues.com/article/S2212-1099(23)00109-7/fulltext" target="_blank" >https://www.valuehealthregionalissues.com/article/S2212-1099(23)00109-7/fulltext</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.vhri.2023.10.001" target="_blank" >10.1016/j.vhri.2023.10.001</a>
Alternative languages
Result language
angličtina
Original language name
The Economic Burden of Biological Drugs in Rheumatoid Arthritis Treatment
Original language description
Objectives: This article aimed to count and compare treatment's direct (only biological drugs) and indirect (loss of productivity) costs in patients with rheumatoid arthritis from 2019 to 2021.Methods: The friction cost approach was used to establish indirect costs. Elasticity factor values and friction period for the Slovak Republic from 2019 to 2021 were determined. Direct drug costs were calculated based on average prices from 2019 to 2021 and the number of dispensed medication packages.Results: The average productivity loss reached euro2984.54 in 2019, euro3338.46 in 2020, and euro3154.01 in 2021. Total indirect costs include productivity loss and sick pay, and from 2019 to 2021 came the values of euro8.4 million, euro10.1 million, and euro8.1 million, respectively. Conclusions: Indirect costs were almost 2.5 to 3 times lower than the biological and targeted treatment costs.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30104 - Pharmacology and pharmacy
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2024
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Value in Health Regional Issues
ISSN
2212-1099
e-ISSN
—
Volume of the periodical
40
Issue of the periodical within the volume
March
Country of publishing house
NL - THE KINGDOM OF THE NETHERLANDS
Number of pages
6
Pages from-to
13-18
UT code for WoS article
001117176500001
EID of the result in the Scopus database
—